Add the specialty areas of your choice to tailor excemed.org to your professional interests.
Save & Create free account
No thanks, just apply selection
I already have an account. Login

User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Fred D. Lublin

Fred D. Lublin
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Meidicine at Mount Sinai
New York, United States

Fred D. Lublin, M.D. is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution. Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center. As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He is a member of the National MS Society National Board of Directors and their medical advisory board. He is Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS using data from a survey of the international MS community. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS. Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He is a Co- Chief Editor of the new journal Multiple Sclerosis and Related Disorders. Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He is the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.

Disclosure of faculty relationships

Declared to have received sources of funding for research from: Acorda Therapeutics Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; NIH; NMSS. He also declared to have been on Consulting Agreements/Advisory Boards/DSMB from: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono, Inc.; Novartis; Teva Neuroscience; Actelion; Sanofi-Aventis; Acorda; Questcor; Roche, Genentech; Celgene; Johnson & Johnson; Revalesio; Coronado Bioscience, Genzyme, MedImmune; Bristol- Myers Squibb, Xenoport, Receptos; Forward Pharma; to-BBB technologies. He declares to be Co-Chief Editor of “Multiple Sclerosis and Related Diseases”. He declared to have Current Financial Interests/Stock Ownership in Cognition Pharmaceuticals, Inc. He finally said: “I may discuss unapproved agents that are in the MS developmental pipeline without any recommendation on their use.”